New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukem ...Middle East

With nearly four years of study follow-up, all-oral, fixed duration IMBRUVICA® + venetoclax reduced the risk of progression or death by 79 percent and demonstrated overall survival (OS) advantage versus chemoimmunotherapy NEW ORLEANS, Dec. 10, 2022 /PRNewswire/ -- The Janssen...

Hence then, the article about new results from the phase 3 glow study of fixed duration treatment with imbruvica ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older unfit patients with previously untreated chronic lymphocytic leukem was published today ( Saturday 10/12/2022 - 07:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukem )

Also on site :

• Merz rejects Zelensky’s ‘concrete date’ for EU membership
• Primary school teacher banned after drinking can of beer in classroom and eating mints after every sip
• Costco Is Selling a Stunningly Soft 3-Piece Quilt Set With a 'Neutral but Unique Print'